🔥 What This Document Is

This is a legal notice filed with the SEC to inform Exicure, Inc. (XCUR) stockholders about a proposed settlement of several shareholder lawsuits. It’s not a typical business update; it's about resolving legal battles against the company's own leaders. The main document is a court-approved notice and the full settlement agreement.

👉 In simple terms: A group of shareholders sued Exicure's former directors and officers, saying they messed up. Now, all sides have agreed to settle the case to avoid a long, expensive trial. This filing explains the deal and tells shareholders what it means for them.

🏢 What The Company Does & Why This Happened

Exicure is a biotech company that was developing drugs using a proprietary technology called spherical nucleic acids (SNAs). The lawsuits allege that between January and December 2021, the company's leadership failed to properly manage data from its studies and made misleading statements to the public about a key drug candidate, XCUR-FXN. This allegedly hurt the company's reputation and finances.

👉 The core accusation: The defendants breached their "fiduciary duties" – a fancy way of saying they failed in their legal responsibility to manage the company and its information properly.

⚖️ The Lawsuits & The Settlement

Three separate legal actions are being settled together:

Illinois Action: A consolidated lawsuit in federal court in Chicago.
Delaware Action: A similar lawsuit in Delaware court.
The Demand: A formal pre-suit demand from a shareholder for the Board to investigate and act.

The Settlement Terms: The company admits no wrongdoing. The defendants continue to deny all allegations. Instead of going to trial, they agreed to settle to avoid the "distraction, costs, and risks of further litigation."

👉 What the company gets: The lawsuits will be dismissed forever, and the company must implement new corporate governance rules (see below). 👉 What the plaintiffs' lawyers get: $675,000 in fees and expenses, paid from the company's insurance (not from Exicure's own money).

📜 The Key Reforms (The Main Benefit)

The heart of the settlement is a list of corporate governance reforms Exicure must adopt and maintain for at least four years. These are designed to prevent the alleged problems from happening again.

Major New Changes:

Research & Data Integrity Oversight Committee: A new Board-level committee (with members who joined after March 2022) must be formed. It will review policies to ensure the integrity of scientific research, experimental data, and regulatory reporting at least annually.
Management-Level Disclosure Committee: A new committee (CEO, CFO, and another senior officer) must be created to review SEC filings and public disclosures for accuracy.
Annual Internal Controls Review: For five years, the Board must annually review how to strengthen internal auditing and compliance, especially concerning FDA regulations.
Better Oversight of Strategic Plans: The CEO must present to the Board at least once a year on exploring strategic alternatives (like potential partnerships or sales of the company).

Other Changes Already Made (Acknowledged by the Settlement):

The Board expanded from six to eight directors.
The charters for the Compensation and Nominating/Governance committees were strengthened.

💰 Financials & Costs

Attorneys' Fees: $675,000 will be paid to the plaintiffs' attorneys by Exicure's insurers. This is for the "substantial benefits" the reforms bring to the company.
Service Awards: The plaintiffs themselves can apply for awards of up to $2,000 each (from the $675,000 fee pool) for their efforts.
Cost to Exicure: The settlement states that the fees are paid by insurance, not from Exicure's assets. The company's main cost is implementing the new governance rules.

🗓️ What's Next & Key Dates

Preliminary Approval: The court gave initial approval on March 19, 2026.
Settlement Hearing: A final hearing is scheduled for June 2, 2026, at 10:30 a.m. in Chicago before Judge Manish S. Shah. The court will decide if the settlement is fair and final.
Objecting to the Settlement: If a stockholder wants to object, they must file a written notice with the court and lawyers by May 12, 2026.
Final Outcome: If the settlement is approved, all lawsuits are dismissed with prejudice (permanently), and the new governance rules are locked in.

⚖️ Big Picture: Strengths & Risks

👍 Strength / Positive: This resolves a major legal distraction. The governance reforms are tangible, concrete improvements that could make Exicure a better-run, more transparent company, potentially reducing future risk. The cost is borne by insurers.
⚠️ Risk / Negative: The settlement is a cost of past issues. The allegations of flawed data and misleading statements about the XCUR-FXN program are serious and highlight historical operational failures. While no liability is admitted, the need for such sweeping reforms points to significant past governance weaknesses.

🧠 The Analogy

Think of this like a board of directors settling a lawsuit that accused the previous coach and team managers of falsifying practice records and misleading the team owners. Instead of going to trial to prove who was right, they agree: the old managers are gone, the team will now hire an independent ethics officer and open all its books to a new oversight committee, and the team's insurance will pay the lawyers' fees. The owners get a promise of better management moving forward.

📇 Key Contacts & People

Plaintiffs' Lead Counsel: Timothy Brown, The Brown Law Firm, P.C. | 767 Third Avenue, Suite 2501, New York, NY 10017 | Tel: (516) 922-5427 | Email: [email protected]
Defendants' Lead Counsel: Douglas L. Shively, Baker & Hostetler LLP | One North Wacker Drive, Suite 4500, Chicago, IL 60606 | Tel: (312) 416-6200 | Email: [email protected]
Individual Defendants (Former Directors/Officers): David A. Giljohann, Brian C. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat, Timothy P. Walbert.
Plaintiffs: Kapil Puri, Yixin Sim, Stourbridge Investments LLC, James McNabb.

🧩 Final Takeaway

This settlement cleans house from past alleged misdeeds at no direct cash cost to Exicure, funded by insurance. Its real price and value are in the four-year commitment to stricter governance and data oversight. For investors, it marks a potential turning point toward better internal controls, but it also confirms the serious flaws that existed in the company's recent past.

EXICURE, INC. — 8-K Filing